Search results

Filters
Close
ADDED DATE
Added date
TOPICS Please select
WATCH / LISTEN / READ TIME
Masterclass on Achievement in the Face of Adversity with Dr Eugene Braunwald
Author(s): Eugene Braunwald , Harriette Van Spall Added: 1 month ago
In this Radcliffe Cardiology Masterclass, Dr Harriette Van Spall (McMaster University, Canada) sits down with cardiology legend Dr Eugene Braunwald (Harvard Medical School, TIMI Study Group) to explore his life, landmark research, and advice for the next generation of cardiovascular clinicians and scientists. This discussion was originally recorded in 2021, and we share it now in remembrance of… View more

Intervention

Prevention & Chronic Conditions
Live Zoster Vaccination Linked to Reduced Cardiovascular Event Risk
Added: 10 months ago Source:  Radcliffe Cardiology
A large-scale, nationwide study from South Korea suggests that vaccination with the live zoster vaccine is associated with a significantly lower risk of various cardiovascular (CV) events in adults aged 50 and older. The findings indicate a protective association that persists for up to 8 years post-vaccination.¹This population-based cohort study analysed data from over 2.2 million individuals… View more

Prevention & Chronic Conditions

Demographic
Aldosterone and Potassium in Heart Failure
Author(s): Laibah Arshad Khan , Adeena Jamil , Stephen J Greene , et al Added: 1 year ago

Prevention & Chronic Conditions

Cardiovascular Kidney Metabolic
Acoramidis Reduces Cumulative CV Events in ATTR-CM
Added: 3 months ago Source:  Radcliffe Cardiology
Transthyretin amyloid cardiomyopathy (ATTR-CM) is a progressive disease associated with a significant burden of recurrent cardiovascular (CV) events. A new post hoc analysis of the ATTRibute-CM trial suggests that acoramidis, an oral transthyretin (TTR) stabiliser, significantly reduces the cumulative burden of these outcomes.¹MethodologyThis exploratory analysis used data from the phase 3,… View more

Cardiovascular Kidney Metabolic

Heart Failure
Heart Disease in Pregnancy: Maternal and Neonatal Risk
Author(s): Rofila Dita Karmia , Mefri Yanni , Yusrawati , et al Added: 5 months ago

Inherited and Congenital Cardiac Conditions

Electrophysiology & Arrhythmia
ESC 25 Hot Line Discussion: BETAMI-DANBLOCK: Beta-Blockers after MI
Author(s): Harriette Van Spall , Dan Atar , Anna Meta Dyrvig Kristensen Added: 9 months ago
ESC Congress 2025 - Long-term beta-blocker therapy after myocardial infarction reduced the primary endpoint of death from any cause or major adverse cardiovascular events.Late-breaker host Dr Harriette Van Spall (McMaster University, CA) sits down with Prof Dan Atar (Oslo University Hospital Ulleval, NO) and Dr Anna Meta Dyrvig Kristensen (Bispebjerg and Frederiksberg Hospital, DK) to discuss the… View more

MI/ACS

Heart Failure
Undiagnosed Sleep Apnoea Linked to Adverse Myocardial Remodelling in Hypertrophic Cardiomyopathy
Added: 8 months ago Source:  Radcliffe Cardiology
Sleep-disordered breathing (SDB), a condition mediated by intermittent hypoxaemia and autonomic dysregulation, is a well-established contributor to cardiovascular morbidity. A new prospective cohort study suggests that patients with hypertrophic cardiomyopathy (HCM) are particularly at risk, revealing a high prevalence of previously undiagnosed SDB in this population. The research links the… View more

Imaging & Diagnostics

Heart Failure
The WICD-MI Study
Author(s): Mathieu Echivard Added: 1 year ago
ESC HFA 25 - The WICD-MI study finds heart failure to be frequent in patients with persistent left ventricular dysfunction after acute myocardial infarction.We are joined onsite by Dr Mathieu Echivard (University Hospital of Nancy, Nancy, FR) to discuss key findings from a study investigating heart failure events in patients with persistent left ventricular dysfunction after acute myocardial… View more

MI/ACS

Heart Failure
Breakthrough Mineralocorticoid Receptor Agonists in Cardiovascular Care
Author(s): Javed Butler , Dinesh Khullar , John JV McMurray , et al Added: 6 months ago
In this expert-led webinar moderated by Dr Vijay Chopra, leading clinicians review current and emerging strategies in aldosterone modulation, hyperkalaemia management, and cardiorenal therapeutics.Dr Javed Butler opens with a practical overview of aldosterone’s central role in heart failure and CKD, emphasising the importance of achieving guideline-directed RAAS inhibitor and MRA dosing. He… View more

Prevention & Chronic Conditions

Heart Failure
REDUCE-IT: CV Outcomes With Icosapent Ethyl by Baseline LDL-C
Author(s): Deepak L Bhatt Added: 1 year ago
In this insightful interview, Dr Deepak Bhatt (Mount Sinai Hospital, US) joins us to discuss findings from a post-hoc analysis of the REDUCE-IT trial, examining how icosapent ethyl affects cardiovascular outcomes across different baseline LDL-C levels.The study included 8,175 statin-treated patients with elevated cardiovascular risk and triglyceride levels between 135-499mg/dL. All participants… View more

Prevention & Chronic Conditions